The January update of an expert panel from the American College of Chest Physicians on the expanding clinical entity of pulmonary hypertension, especially pertinent to the transplant community.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Heart Failure - Nonischemic
Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report
September 5, 2019
August 13, 2019
The translational value for cardiac transplantation of this prospective multi-centre clinical study of vasodilation in amyloidosis remains to be evaluated.
March 26, 2019
The investigators published the final analysis of the MOMENTUM 3 trial comparing the fully magnetically levitated centrifugal continuous-flow HeartMate 3 pump to the mechanical-bearing axial continuous-flow HeartMate II pump.
The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships
February 7, 2019
In the February issue of The Annals, The Society of Thoracic Surgeons published the first annual report after the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) joined the STS National Database in January 2018. This report summarizes the outcomes in patients (≥19 years of age) undergoing durable MCS implant b
February 5, 2019
In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD) to outcomes for patients treated since the device came to market.
Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
January 18, 2019
A good attempt to shed some light into the somewhat challenging concept of heart failure with preserved ejection fraction, on the occasion of a small randomized controlled trial on albuterol.
Six-Month Outcomes After Treatment of Advanced Heart Failure With a Full Magnetically Levitated Continuous Flow Left Ventricular Assist Device: Report From the ELEVATE Registry
October 23, 2018
A post-market study (ELEVATE registry) of the fully magnetically levitated continuous flow HeartMate III left ventricular assist device (LVAD) found no pump thrombosis in 463 patients in Europe and Kazakhstan.
May 15, 2018
A sober editorial on a murine model of induced cardiac failure, which highlights the challenges of translating animal omics to humans
March 12, 2018
An interesting two-year report from the MOMENTUM 3 randomized controlled trial comparison of HeartMate 3 and II, the analysis performed by Abbott. Although stroke and reoperation were clearly lower with the latest technology, reflected in the lower LDH measurements, there was bafflingly no improvement in survival.